STOCK WATCH

HEMOGENYX Pharmaceuticals saw its share price almost triple after a cryptic tweet. On Sunday evening the firm, which is involved in bone marrow and blood stem cell transplants, took to Twitter to announce ‘a serious breakthrough in the lab’. Yesterday the firm responded after its share price spiked, confirming it had filed a provisional patent application in relation to a potential leukaemia treatment. Shares rocketed 184.7pc, or 3.9p, to 6.05p.